Literature DB >> 182685

Cyclic adenosine 3':5'-monophosphate phosphodiesterase. Distinct forms in human lymphocytes and monocytes.

W J Thompson, C P Ross, W J Pledger, S J Strada, R L Banner, E M Hersh.   

Abstract

Adenosine 3':5'-monophosphate (cyclic AMP) phosphodiesterase activity of normal human peripheral blood leukocyte suspensions containing 90% lymphocytes and 10% monocytes showed anomalous kinetic behavior indicative of multiple enzyme forms. Kinetic analyses of purified lymphocyte (99%) or monocyte preparations (95%) indicated that only one type of phosphodiesterase was present in each cell type. None of the preparations contained any detectable guanosine 3':5'-monophosphate (cyclic GMP) hydrolytic activity. The lymphocyte enzyme had an apparent Km congruent to 0.4 muM for cyclic AMP and Vmax congruent to 0.5 picomoles/min/10(6) cells. These kinetic parameters were confirmed by several cell purification techniques used alone and sequentially. Sedimentation velocity analyses indicated that the higher Km monocyte enzyme had a molecular weight near 45,000 and that the lower Km lymphocyte enzyme most likely had a molecular weight near 98,000. A variety of procedures led to a loss of the higher molecular weight, high affinity enzyme leaving only the enzyme of 45,000 daltons with a much lower substrate affinity. A long term, stable human lymphoblastoid cell line had cyclic AMP phosphodiesterase activity that was similar to the lymphocyte enzyme by both physical and kinetic criteria. Lymphocyte cyclic AMP phosphodiesterase appears to be a soluble enzyme whose pH and temperature optima and cationic requirements are similar to those of other mammalian phosphodiesterases. The distinct cyclic AMP phosphodiesterase forms of these cells may possibly represent the basic, active subunit of mammalian cyclic nucleotide phosphodiesterases. We hypothesize that the extremely high affinity cyclic AMP phosphodiesterase of normal lymphocytes plays an important role in the regulation of normal function in these cells, and also in the rapid proliferative responses characteristic of the stimulated lymphocyte.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182685

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Heat-stable low molecular weight form of phosphodiesterases from bovine pineal gland.

Authors:  K Sankaran; I Hanbauer; W Lovenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

2.  Identification and characterization of a Ca2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line.

Authors:  P M Epstein; S Moraski; R Hachisu
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

3.  Regulation of cyclic AMP phosphodiesterase from Mucor rouxii by phosphorylation and proteolysis. Interrelationship of the activatable and insensitive forms of the enzyme.

Authors:  N Kerner; S Moreno; S Passeron
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

4.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.

Authors:  J E Souness; M Griffin; C Maslen; K Ebsworth; L C Scott; K Pollock; M N Palfreyman; J A Karlsson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

5.  Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.

Authors:  K H Banner; N M Roberts; C P Page
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

6.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.

Authors:  M A Giembycz; C J Corrigan; J Seybold; R Newton; P J Barnes
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 7.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

8.  Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.

Authors:  G Dent; M A Giembycz; K F Rabe; P J Barnes
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

9.  Localization of 3',5'-cyclic adenosine monophosphate phosphodiesterase (cAMP-PDEase) activity in isolated bovine thyroid plasma membranes.

Authors:  A E Kalderon; J W Dobbs; M L Greenberg
Journal:  Histochemistry       Date:  1980

10.  Histamine induced elevation of cyclic AMP phosphodiesterase activity in human monocytes.

Authors:  C A Holden; S C Chan; S Norris; J M Hanifin
Journal:  Agents Actions       Date:  1987-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.